H.R. 2529: Convenient Contraception Act
This bill, known as the Convenient Contraception Act, aims to amend existing health care regulations in the United States to enhance access to contraceptives for individuals enrolled in group and individual health insurance plans. Here’s a breakdown of what the bill proposes:
Key Requirements
- The bill requires group health plans and health insurance issuers to allow enrollees to obtain a maximum of a 365-day supply of contraceptives. This means that individuals can acquire their contraceptives all at once, rather than needing to obtain them in smaller quantities, which may require more frequent visits to a pharmacy.
- Enrollment in these health plans must include this option without imposing any additional out-of-pocket costs, ensuring that individuals can access this supply of contraceptives without facing financial barriers.
- The new provisions would come into effect starting from January 1, 2026. This means that after this date, all qualified insurance plans must comply with the new requirements.
Outreach Efforts
To ensure that the changes are effectively communicated, the bill mandates that within 90 days of its enactment, the Secretaries of Health and Human Services, Labor, and Treasury must carry out outreach activities. These activities are intended to:
- Inform healthcare providers about the new benefits related to contraceptive supplies.
- Educate current and prospective enrollees about their rights and options regarding contraceptive access under their health plans.
Purpose of the Bill
The overarching goal of the Convenient Contraception Act is to improve access to contraceptive methods, which may support comprehensive reproductive health care and empower individuals with the option to manage their contraceptive needs more effectively. By allowing for a larger supply of contraceptives, the bill seeks to reduce the frequency of visits necessary for obtaining contraceptives, thereby simplifying the process for users.
Relevant Companies
- PFE (Pfizer Inc.): Pfizer manufactures various contraceptive products and may see changes in demand based on increased access outlined by the bill.
- JNJ (Johnson & Johnson): As a producer of medical products that include contraceptive options, any changes in regulations surrounding accessibility could influence their sales and inventory decisions.
- BAYRY (Bayer AG): Bayer produces a variety of contraceptive solutions and may be directly impacted by shifts in healthcare coverage resulting from this legislation.
This is an AI-generated summary of the bill text. There may be mistakes.
Sponsors
4 bill sponsors
Actions
2 actions
| Date | Action |
|---|---|
| Apr. 01, 2025 | Introduced in House |
| Apr. 01, 2025 | Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
Corporate Lobbying
0 companies lobbying
None found.
* Note that there can be significant delays in lobbying disclosures, and our data may be incomplete.
